StockTipsArenaBeta

BUY Nephrocare Health Services Limited — Axis Securities

BUYNephrocare Health Services Limited
Nephrocare Health Services share price target & all analyst calls

byAxis SecuritiesHorizon: 1 year31 Oct 2026via Business Today

Entry₹609.55Inferred
Target₹710
Total upside +16.48%
Stop lossNot given
CMP₹601.751d ago
Active-1.28%+17.99%upside left 12 mo left
Follow Axis Securities for new calls(69% target hit, 843 closed calls)Get alertsWatch NEPHROPLUS for new buy/sell callsGet alertsSee 4 other Long-term calls on NEPHROPLUSSee 542 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST
16 supporting3 neutral4 opposing
Supports the BUY call (16)

Nephrocare Health Services reported H1 FY27 revenue of Rs 585.2 crore, up 23.6% YoY, and adjusted PAT of Rs 76.1 crore, up 34.7% YoY, driven by network expansion and increased treatment volumes.

BSE · Company Update·3 Nov · 3d ago

(opens in new tab)

An Uzbekistan court has invalidated a tax demand of approximately ₹14.79 crore against the company's subsidiary, Nephrocare Health Services Central Asia LLC, citing procedural irregularities.

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·2 Nov · 4d ago

(opens in new tab)

Nephrocare Health Services Limited's subsidiary, Nephrocare Health Care Services, Philippines Inc., has entered into an asset transfer agreement to acquire a dialysis center in Quezon City, Philippine

NSE · Agreements·27 Oct · 1w ago

(opens in new tab)

Nephrocare Health Services' step-down subsidiary in the Philippines has entered into an asset transfer agreement to acquire a dialysis center from JCM Summit Health Inc.

BSE · Company Update·27 Oct · 1w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·8 Sept · 2mo ago

Neutral / worth noting (3)

Outcome of the Board meeting held on November 3, 2026 for considering and approving the financial results for the period ended September 30, 2026.

BSE · Board Meeting·3 Nov · 3d ago

(opens in new tab)
Weighs against the BUY call (4)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Nephrocare Health Services

All analyst calls on Nephrocare Health Services

More from Axis Securities

Every call and its outcome